This session will discuss current evidence and emerging treatment options in the management of SCLC. An overview of SCLC will be provided including definitions, staging, epidemiology, pathology and ongoing clinical trials. The rationale for new systemic agents and immunotherapy will be reviewed. Pertinent controversies including the timing of radiation and commonly delivered dose fractionations in limited stage SCLC; as well as the merits of consolidative thoracic radiation and stereotactic radiotherapy in extensive stage SCLC will be discussed. Finally, the current role of prophylactic cranial irradiation (PCI) will be discussed in the context of emerging strategies such as hippocampal sparing PCI, MRI surveillance, immunotherapy and intracranial stereotactic radiotherapy.
Learning Objectives:
? Review the evidence for optimal dose and timing of radiotherapy for limited stage SCLC
? Discuss the controversies of radiation in extensive stage (and oligometastatic) SCLC
? Review the rationale for advanced radiation modalities, such as hippocampal-sparing prophylactic cranial irradiation and stereotactic radiotherapy
Presentations:
8:00 AM - 8:15 AM
The Basics of Small Cell Lung Cancer Speaker: Shankar Siva, PhD, MBBS, FRANZCR – Peter MacCallum Cancer Centre
8:15 AM - 8:30 AM
New Approaches in Limited Stage SCLC Speaker: David Palma, MD, PhD – London Health Sciences Centre
8:30 AM - 8:45 AM
Radiotherapy in Extensive Stage SCLC - Hypofractionation or Hype? Speaker: Alexander Louie, MD, PhD, MSc, FRCPC – Sunnybrook Health Sciences Centre
8:45 AM - 9:00 AM
Prevention and Management of Brain Metastases in SCLC - Optimize Cognition or Control? Speaker: Chad Rusthoven, MD – University of Colorado Denver
